CEVR Participation at ISPOR 2025

CEVR faculty and researchers will present their research during several discussion and poster sessions at ISPOR 2025:

Wednesday, May 14

• Issues Panel
  • 10:15 – 11:15: What’s Next? Year 1 Learnings of Evidence Planning for IRA Drug Price Negotiation
    • Moderator: Taylor T Schwartz, Avalere, Valencia, CA, United States
    • Speakers: Peter Neumann, ScD, Tufts Medical Center (CEVR); Michael Ciarametaro, BS, MA, MBA, Avalere Health; Russ Montgomery, PhD, GSK US
  • 3:15 – 4:15: The Three Percent Discount Rate: Is It Really Time to Move On: How Much Does It Matter?
    • Moderator: Joshua Cohen, PhD, Tufts Medical Center (CEVR)
    • Speakers: David J Vanness, PhD, The Pennsylvania State University; Jason Shafrin, PhD, FTI Consulting
  • 5:00 – 6:00: Challenges in the Implementation of Generalized Cost-Effectiveness Analysis (GCEA): Debating a Path Forward
    • Moderator: Meng Li, MS, PhD, Tufts Medical Center (CEVR)
    • Speakers: Jason Shafrin, PhD, FTI Consulting; Darius Lakdawalla, PhD, University of Southern California; Melanie D Whittington, MS, PhD, Leerink Center for Pharmacoeconomics and Tufts Medical Center (CEVR)
• Workshops
  • 1:45 – 2:45: HEOR Meets Investing—Why Are Banks and VCs Collaborating With Health Economists?
    • Moderator: Meng Li, MS, PhD, Tufts Medical Center (CEVR)
    • Speakers: William Canestaro, PhD, Washington Research Foundation; Richard Xie, PhD, RA Capital Management; Melanie D Whittington, MS, PhD, Leerink Center for Pharmacoeconomics and Tufts Medical Center (CEVR)
  • 5:00 – 6:00: Introducing HEMA: An International Working Group for Principled Assessment of Novel HTA Methods and Processes
    • Moderator: Dan Ollendorf, MPH, PhD, Institute for Clinical & Economic Review and CEVR
    • Speakers: Zal Press, BSc, Patient Commando; Lotte Steuten, MSc, PhD, Office of Health Economics; Nicole Mittmann, MSc, PhD, Canada's Drug Agency
• Poster
  • Poster Session 1
    • 10:30 – 1:30: Use of Health Technology Assessments in Specialty Drug Coverage Decisions by U.S. Commercial Health Plans
      • Enright D, Chambers J

Thursday, May 15

• Workshops
  • 10:15 – 11:15: Rethinking Clinical Meaningfulness and Value Assessment in the Context of Chronic Progressive Diseases
    • Moderator: William L Herring, PhD, RTI Health Solutions
    • Speakers: Cheryl Coon, PhD, Critical Path Institute; William Lenderking, PhD, William R Lenderking, LLC; Melanie D Whittington, MS, PhD, Leerink Center for Pharmacoeconomics and Tufts Medical Center (CEVR)
  • 1:45 – 2:45: Integrating Financial Risk Protection Into Economic Evaluation and Policy Decision Making: What, Why, and How?
    • Moderator: Stéphane Verguet, PhD. Harvard T.H. Chan School of Public Health.
    • Speakers: Sara Khor, PhD, Stanford University; Tara Lavelle, PhD, Tufts Medical Center (CEVR); Boshen Jiao, MPH, PhD, University of Southern California
• Fast Facts
  • 11:30 – 12:00: Flash Back! A Look Back at Value in Health Papers of the Year for 2023 and 2024
    • Speakers: Nancy Devlin, PhD, University of Melbourne; C. Daniel Mullins, PhD, University of Maryland; Aurelie Meunier, MSc, Putnam; Peter Neumann, ScD, Tufts Medical Center (CEVR)
• Posters
  • Poster Session 3: 10:30 – 1:30
    • Use of Clinical Outcome Assessments in Specialty Drug Coverage Policies
      • Rucker J, Poon JLL, LaMountain F, Lin Y, Beinfeld M, Klopchin M, Chambers J
    • US Commercial Health Plan Coverage of Oncology Therapies: 2017-2024
      • Rucker J, Enright D, Beinfeld M, Liljas B, Chambers J
  • Poster Session 4: 4:00 -7:00
    • What Drug Characteristics Explain the Wide Range of Manufacturer Rebates?
      • Beinfeld M, LaMountain F, Phillips G, Hughes T, Neumann P, Chambers J
    • Estimating the U.S. Economic Burden of Autoimmune Diseases: A Pilot Systematic Literature Review
      • • Shi L, Lin P, Mullin S, Wang X, Cohen J, Phillips G